May 2008 Volume 26 Number 5, pp 475 - 588
Visit Nature Biotechnology online to browse the journal.
Now available at http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0dXt0EP
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0aAP0EN
Alternatively, to recommend a subscription to your library, please visit
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BRQi0Et
Bioentrepreneur: an online resource for budding business in the life sciences.
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BkE0EN
=====================================================================
Ten new research highlights have just gone live on A-IMBN RESEARCH.
Access is free!
Breaking Down Memories
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BtmJ0EQ
Original reference: Science 319, 1253-1256 (2008)
T Cells Work Away from Home
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BtmK0ER
Original reference: Science 319, 198-202 (2008)
Protective medicine under the tongue
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BtmL0ES
Original reference: SPNAS 105, 1644-1649 (2008)
Plus more!
=====================================================================
=====================================================================
Regenerative Medicine Scientists, All levels - UK and US
As our population ages, we become more susceptible to degenerative
diseases and many other disabilities.If you have the right knowledge,
experience and pioneering attitude, you could help us change the way
the world will think about healthcare.To find out more please visit
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buh50Ez
=====================================================================
=====================================================================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BpT40EZ
=====================================================================
=====================================================================
FREE TRIAL AVAILABLE: SciBX: Science-Business eXchange
To keep up with the most important emerging science you could scan all of the top journals and hope you have enough time left to read the key papers - or you can read SciBX every week.
SciBX - Identifying and distilling key papers, so you have time to read them.
To find out which papers made it into SciBX this week, sign up for a FREE TRIAL at http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Burw0EH
SciBX: Science-Business eXchange - new from the makers of Nature and BioCentury
=====================================================================
=====================================================================
----------------------
EDITORIALS
----------------------
Looking forward, looking back p475
Amgen's retrospective sortie into personalized Vectibix treatment poses some difficult questions for regulators concerning the oversight of companion diagnostics.
doi:10.1038/nbt0508-475
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buh60E1
Nothing to see here p476
Based on one company's past poor publishing practices, a top-tier medical journal misguidedly stigmatizes any paper from industry.
doi:10.1038/nbt0508-476
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buh70E2
----------------------
NEWS
----------------------
Regulators scramble to tighten loopholes after heparin debacle pp477 - 478
Hepeng Jia
doi:10.1038/nbt0508-477
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuhZ0Ec
EU to monitor for Chinese GM rice p478
Brady Huggett
doi:10.1038/nbt0508-478
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buh80E3
Inhaled insulin's last gasp? pp479 - 480
Jim Kling
doi:10.1038/nbt0508-479
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiA0EE
Courts deny Pfizer access p480
Trisha Gura
doi:10.1038/nbt0508-480
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiB0EF
Patent threat in emerging economies shifts to biotech pp481 - 483
Killugudi Jayaranam
doi:10.1038/nbt0508-481
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiC0EG
New Alzheimer's endpoints? p482
Susan Aldridge
doi:10.1038/nbt0508-482a
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiD0EH
GM grass trials blocked p482
Jeffrey L Fox
doi:10.1038/nbt0508-482b
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiE0EI
Bush pushes plant energy p483
Jeffrey L Fox
doi:10.1038/nbt0508-483a
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiF0EJ
Changes for ESAs p483
B J Spalding
doi:10.1038/nbt0508-483b
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiG0EK
Dynavax trial halted p484
Laura DeFrancesco
doi:10.1038/nbt0508-484a
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiH0EL
No way out for small public firms? pp484 - 485
Peter Mitchell
doi:10.1038/nbt0508-484b
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiI0EM
M&A not the only solution p485
Brady Huggett
doi:10.1038/nbt0508-485a
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiJ0EN
IL-1 trap go-ahead p485
Mark Ratner
doi:10.1038/nbt0508-485b
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiK0EO
DATA PAGE
Biotech slumps in Q1 p486
Stacy Lawrence
doi:10.1038/nbt0508-486
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiL0EP
NEWS FEATURE
The special treatment pp487 - 489
The special protocol assessment introduced only six years ago by the US Food and Drug Administration (FDA) to facilitate clinical trials is gaining popularity. Randy Osborne finds out why.
Randy Osborne
doi:10.1038/nbt0508-487
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiM0EQ
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Learning from each other pp491 - 494
An industry academic liaison officer and a university technology-transfer professional in the UK canvass their peers to provide some pointers for how to streamline the technology-transfer process between companies and academia.
Tim Sparey and Francesca Gliubich
doi:10.1038/bioe.2008.4
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiO0ES
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
HIV vaccine trials in India p495
Seth Berkley
doi:10.1038/nbt0508-495
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiP0ET
Response to HIV vaccine trials in India p496
doi:10.1038/nbt0508-496a
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiQ0EU
Demonizing phytate pp496 - 497
AbulKalam M Shamsuddin
doi:10.1038/nbt0508-496b
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiR0EV
Response to Demonizing phytate pp497 - 498
doi:10.1038/nbt0508-497
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiS0EW
Legal issues for biological research standards pp498 - 499
Jorge L Contreras
doi:10.1038/nbt0508-498
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiT0EX
Off the rails or on the mark? pp499 - 500
Jack A Heinemann
doi:10.1038/nbt0508-499
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiU0EY
Off the rails or on the mark? pp500 - 501
Joanna Chataway, Joyce Tait and David Wield
doi:10.1038/nbt0508-500
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiV0EZ
COMMENTARY
The impact of greed on academic medicine and patient care pp503 - 507
John V Frangioni
doi:10.1038/nbt0508-503
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiW0Ea
Article: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiX0Eb
----------------------
FEATURES
----------------------
Is personalized medicine finally arriving? pp509 - 517
It's no gold rush, but dozens of players are emerging in personalized medicine, with biotechs, big and small, leading the way. Some big pharma companies and even payers remain skeptical, but economics aside, the real winners will be patients.
Malorye Allison
doi:10.1038/nbt0508-509
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiY0Ec
PATENTS
Designing around patents: a guideline pp519 - 522
An analysis of US Federal Circuit decisions shows strategies for designing around patents.
Shyh-Jen Wang
doi:10.1038/nbt0508-519
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiZ0Ed
Recent patent applications in drug screening p523
doi:10.1038/nbt0508-523
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buia0Ek
----------------------
NEWS AND VIEWS
----------------------
Flavivirus DNA vaccine with a kick pp525 - 526
Immunization with single-round infectious particles enhances potency of a DNA vaccine against West Nile virus.
Alan D T Barrett
doi:10.1038/nbt0508-525
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buib0El
Customized signaling with reconfigurable protein scaffolds pp526 - 528
Engineering protein scaffolds creates signaling networks with novel properties.
Patrick Guye and Ron Weiss
doi:10.1038/nbt0508-526
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buic0Em
Retinal anti-angiogenesis by a new route pp528 - 529
A regulator of VEGF signaling shows therapeutic potential for retinal disease.
Roy Bicknell
doi:10.1038/nbt0508-528
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buid0En
Research highlights p530
doi:10.1038/nbt0508-530
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buie0Eo
================================================================
================================================================
Are you looking for a partner?
Let us help you select suitable Antibody interaction partners by using the
Attana A100(R) C-Fast system: label-free, molecular interaction analysis in real time.
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Bpln0Ev
================================================================
================================================================
----------------------
COMPUTATIONAL BIOLOGY
----------------------
ANALYSIS
A modular approach for integrative analysis of large-scale gene-expression and drug-response data pp531 - 539
Zoltan Kutalik, Jacques S Beckmann and Sven Bergmann
doi:10.1038/nbt1397
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buif0Ep
Article: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buig0Eq
----------------------
RESEARCH
----------------------
PERSPECTIVE
The minimum information about a genome sequence (MIGS) specification pp541 - 547
Dawn Field et al.
doi:10.1038/nbt1360
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buih0Er
Article: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buii0Es
BRIEF COMMUNICATION
CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression pp549 - 551
Stephen C Hyde et al.
doi:10.1038/nbt1399
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buij0Et
Article: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buik0Eu
ARTICLES
Genome sequencing and analysis of the biomass-degrading fungus Trichoderma reesei (syn. Hypocrea jecorina) pp553 - 560
Diego Martinez et al.
doi:10.1038/nbt1403
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buil0Ev
Article: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buim0Ew
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics pp561 - 569
Akin Akinc et al.
doi:10.1038/nbt1402
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buin0Ex
Article: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buio0Ey
LETTERS
Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus pp571 - 577
David C Chang et al.
doi:10.1038/nbt1400
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buip0Ez
Article: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buiq0E1
The impact of target site accessibility on the design of effective siRNAs pp578 - 583
Hakim Tafer et al.
doi:10.1038/nbt1404
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buir0E2
Article: http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buis0E3
=====================================================================
=====================================================================
This alert is sponsored by Qlucore
Efficiently analyze large data sets.
Intuitive methods help you find patterns and structure with a few mouse clicks. Immediate response is guaranteed for all data sets (example: gene expression data) up to size 500 x 100 000 when you use a normal PC.
Download free evaluation at http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0BuiN0ER
=====================================================================
=====================================================================
----------------------
NATUREJOBS
----------------------
CAREERS AND RECRUITMENT
Identifying a robust pool of leadership candidates pp585 - 586
Strategies for finding the right hire in life-science recruiting.
Bruce Rychlik
doi:10.1038/nbt0508-585
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buit0E4
PEOPLE
People p588
doi:10.1038/nbt0508-588
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Buiu0E5
=====================================================================
=====================================================================
Nature Reviews Stem Cell Collection
Free online access
Stem-cell research has a history of more than 20 years, and has made
some outstanding contributions to our understanding of haematopoiesis
and embryology. The Nature Reviews journals present a Stem Cell Collection,
which includes Research Highlights, Reviews and Perspectives articles from
Nature Reviews Cancer, Nature Reviews Immunology
and Nature Reviews Molecular Cell Biology.
All these articles will be available free online for six months at:
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Bqfi0El
=====================================================================
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at:
http://ealerts.nature.com/cgi-bin24/DM/y/ekmy0Xztnp0HjC0Zzu0Eo
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2008 Nature Publishing Group
=====================================================================
